Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Cyramza (ramucirumab; Eli Lilly/Shire) Drug Analysis Report 2018 - ResearchAndMarkets.com

Research and Markets
Posted on: 15 Feb 18

The "Drug analysis: Cyramza" drug pipelines has been added to ResearchAndMarkets.com's offering.

Cyramza (ramucirumab; Eli Lilly/Shire) is a fully human vascular endothelial growth factor receptor (VEGFR)-2-directed immunoglobulin G1 monoclonal antibody that binds to the extracellular domain of VEGFR-2 found on tumor vasculature.

The VEGF protein is an essential component of the angiogenesis pathway, which is critical for blood vessel formation, tumor growth, invasion, and metastasis. Cyramza inhibits tumor angiogenesis by preventing VEGF ligands VEGF-A, VEGF-C, and VEGF-D from binding to and activating the VEGFR-2 receptor, which in turn prevents the proliferation and migration of endothelial cells necessary for angiogenesis to occur. The lack of new blood vessels starves the tumors of their nutrient supply, resulting in tumor growth inhibition.

Product Profiles

  1. Cyramza: Colorectal cancer (CRC)
  2. Cyramza: Hepatocellular carcinoma (HCC)
  3. Cyramza: Bladder cancer
  4. Cyramza: Non-small cell lung cancer (NSCLC)
  5. Cyramza: Gastric cancer

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/l9tzpz/cyramza?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180215006132/en/

Business Wire
www.businesswire.com

Last updated on: 15/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.